Sir,Myelosuppression is frequently observed during treatment with the multi tyrosine kinase inhibitors (TKIs) (Motzer et al, 2007; Bhojani et al, 2008). The frequency and severity of myelosuppression varies among the drug class with sunitinib being a relative myelotoxic compound leading to leukopenia and thrombocytopenia in 56–78% and 41–65% of the patients, respectively (Demetri et al, 2006; Motzer et al, 2007).
British Journal of Cancer 103, 757-758 (24 August 2010) | doi:10.1038/sj.bjc.6605813
No comments:
Post a Comment